Group 1 - The major shareholder Beijing Yidongxing Equity Investment Center (Limited Partnership) held 5,522,738 shares, accounting for 7.10% of the total share capital before the reduction plan [1] - Shareholder Zhao Yanxing directly held 3,468,312 shares, representing 4.46% of the total share capital, both of which are tradable shares obtained before the company's initial public offering [1] - The reduction plan involved a maximum of 1,165,000 shares, not exceeding 1.50% of the total share capital, for both Yidongxing and Zhao Yanxing due to personal funding needs [1] Group 2 - As of December 25, 2025, Yidongxing reduced its holdings by 289,338 shares, which is 0.37% of the total share capital, while Zhao Yanxing reduced his holdings by 293,362 shares, accounting for 0.38% of the total share capital [2] - The reduction plan was completed within the disclosed time frame, and the actual reduction was consistent with the previously announced plan [2][3] - The execution partner of Yidongxing changed from Zhao Yanxing to Lu Zhongda, resulting in Yidongxing no longer being recognized as having a concerted action relationship with Zhao Yanxing [2]

证券代码：688058 证券简称：宝兰德 公告编号：2025-052 北京宝兰德软件股份有限公司 持股 5%以上股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持有的基本情况 本次减持计划实施前，北京宝兰德软件股份有限公司（以下简称"公司"）持 股 5%以上股东北京易东兴股权投资中心（有限合伙）（以下简称"易东兴"）持有 公司股份 5,522,738 股，占公司总股本的比例为 7.10%；股东赵艳兴先生直接持 有公司股份 3,468,312 股，占公司总股本的比例为 4.46%。上述股份均为无限售 流通股且来源于公司首次公开发行前及资本公积转增股本取得的股份。 减持计划的实施结果情况 公司于 2025 年 9 月 4 日披露了《北京宝兰德软件股份有限公司持股 5%以上 股东减持股份计划公告》（公告编号：2025-044），因自身资金安排，易东兴计 划以集中竞价、大宗交易的方式减持其所持有的公司股份合计不超过 1,165,000 股，即不超过公司总股本的 1.50%。因 ...

Core Viewpoint - The company Baolande (688058.SH) has completed its share reduction plan as notified by shareholders Yi Dongxing and Zhao Yanxing, with specific details on the number of shares reduced and their percentage of total share capital [1] Group 1 - Yi Dongxing has cumulatively reduced 289,300 shares, representing 0.37% of the total share capital [1] - Zhao Yanxing has cumulatively reduced 293,400 shares, representing 0.38% of the total share capital [1] - The share reduction plan was completed within the specified time frame [1]

Core Viewpoint - The announcement details the completion of a share transfer agreement between the controlling shareholder of Beijing Baolande Software Co., Ltd. and Tianyang Hongye Technology Co., Ltd., involving the transfer of 5,830,000 shares at a price of 26.56 yuan per share, totaling approximately 154.84 million yuan. Group 1: Share Transfer Agreement - On November 3, 2025, the controlling shareholder, Mr. Yi Cundao, signed a share transfer agreement to transfer 5,830,000 unrestricted circulating shares to Tianyang Technology at a price of 26.56 yuan per share, representing 7.50% of the company's total share capital, with a total transaction value of 154,844,800 yuan [2]. - The share transfer has received compliance confirmation from the Shanghai Stock Exchange and the China Securities Depository and Clearing Corporation, with the transfer date set for December 19, 2025 [2][5]. - The transferee, Tianyang Technology, has committed not to reduce its holdings of the transferred shares within 12 months following the completion of the share transfer registration [3][8]. Group 2: Impact on Company Control - The share transfer does not involve a tender offer and will not result in a change in the controlling shareholder or actual controller of the company, ensuring that the company's stable operations remain unaffected [3][7]. - The completion of the share transfer registration has been confirmed, and the payment for the share transfer has been made in accordance with the agreement [5].

Core Viewpoint - The company Baolande (688058.SH) announced a share transfer agreement where its controlling shareholder, Mr. Yi Cundao, will transfer 5.83 million shares at a price of 26.56 yuan per share to Tianyang Hongye Technology Co., Ltd., representing 7.50% of the company's total share capital, for a total transaction value of 155 million yuan [1] Summary by Categories Share Transfer Details - Mr. Yi Cundao will transfer 5.83 million unrestricted circulating shares at a price of 26.56 yuan per share [1] - The total value of the share transfer amounts to 155 million yuan [1] - The transaction has received compliance confirmation from the Shanghai Stock Exchange [1] Regulatory Approvals - The share transfer has been confirmed by the China Securities Depository and Clearing Corporation Limited with a securities transfer registration confirmation [1] - The transfer date is set for December 19, 2025 [1]

2025年11月3日，北京宝兰德软件股份有限公司（以下简称"公司 "、 "上市公 司 "或"宝兰德 "）控股股东、实际控制人易存道先生与天阳宏业科技股份有限公司（ 以下简称"天阳科技"、"受让方"）签署了《股份转让协议》，易存道先生拟通过 协议转让方式将其直接持有的公司无限售条件流通股5,830,000股以 26.56元/股的价格 转让给天阳科技，占公司总股本的7.50%，股份转让总价款154,844,800元。 本次协议转让交易已取得上海证券交易所的合规性确认，并已经取得中国 证券登记结算有限责任公司出具的《证券过户登记确认书》，过户时间为2025年 12月19日，过户股份数为5,830,000股，占公司股份总数的7.50%，股份性质为无限 售流通股。 本次协议转让股份事项的受让方承诺在标的股份过户登记完成后12个月内 不对外减持标的股份。 证券代码：688058 证券简称：宝兰德 公告编号：2025-051 北京宝兰德软件股份有限公司 关于控股股东协议转让部分股份完成过户 登记的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载 、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 ...

Core Viewpoint - Baoland's stock closed at 26.6 yuan on December 12, 2025, with a market capitalization of 2.068 billion yuan, reflecting a slight decline of 0.23% from the previous trading day [1] Group 1: Stock Performance - The stock opened at 26.6 yuan, reached a high of 27.08 yuan, and a low of 26.51 yuan during the trading session [1] - The trading volume for the day was 26.5528 million yuan, with a turnover rate of 1.28% [1] Group 2: Government Subsidy - The company announced it received a government subsidy of 10 million yuan, which is related to its revenue [1] - According to the Accounting Standards for Enterprises No. 16, this subsidy is expected to have a positive impact on the company's operating performance [1] - The specific accounting treatment and impact on profit and loss will be confirmed by the annual audit results [1]

Group 1 - The core point of the article is that Baoland has received a government subsidy of 10 million yuan, which is expected to have a positive impact on the company's operating performance [2] Group 2 - The government subsidy is categorized as a revenue-related grant [2] - The announcement was made on the evening of December 12 [2]

Group 1 - Shouyao Holdings is planning to issue H-shares and list on the Hong Kong Stock Exchange, with discussions ongoing with intermediaries regarding the specifics of the listing [1] - Jiangsu Guoxin's subsidiary, Guoxin Mazhou, has completed the trial operation of a 1000MW coal-fired power unit, which is set to officially commence operations on December 12, 2025 [2] - Yuekang Pharmaceutical's mRNA tumor vaccine has received clinical trial approval from the National Medical Products Administration for treating advanced solid tumors [3] Group 2 - Dongli New Science plans to invest 666 million yuan in the restructuring of SAIC Hongyan, acquiring approximately 14.66% equity post-restructuring [4] - Longsheng Technology is set to invest approximately 350 million yuan in the establishment of an intelligent robot innovation center in Wuxi [5] - Shangwei Co. has received a government subsidy of 2.212 million yuan, which accounts for 13.53% of its audited net profit for 2024 [6] Group 3 - Anglikang has received drug registration certificates for Diclofenac Sodium Enteric-Coated Tablets and approval for a supplemental application for Sacubitril/Valsartan Sodium Tablets [7] - Guangzhou Development has received acceptance notices for the registration of 8 billion yuan in medium-term notes and 6 billion yuan in short-term financing bonds [8] - Kebo Da plans to increase capital by 21.2 million euros (approximately 174 million yuan) in its wholly-owned subsidiary in Germany [9][10] Group 4 - Changguang Huaxin has received a total of 11.6672 million yuan in government subsidies, including 8.0552 million yuan related to income [11] - Haizheng Pharmaceutical's subsidiary has received a European Pharmacopoeia suitability certificate for its raw material [12] - Qianjin Pharmaceutical's subsidiary has received a drug registration certificate for Lurasidone Hydrochloride Tablets, used for treating schizophrenia [13] Group 5 - Daimai Co. has received a warning letter from the Shanghai Securities Regulatory Bureau due to failure to timely disclose a significant event related to a fire incident [14] - ST Changyao's subsidiary has recently ceased production due to financial difficulties and competitive pressures in the photovoltaic industry [15] - Guodian Power is investing in the construction of a 2×1000MW expansion project at the Ganbi Power Plant, with a total dynamic investment of 7.218 billion yuan [16] Group 6 - Kaichuang International's subsidiary has completed the handover of a tuna purse seine vessel, expected to be operational by 2026 [16] - Tieke Rail plans to sign an energy management agreement for a distributed photovoltaic project, which is expected to save approximately 1.441 million yuan in electricity costs over 25 years [18] - Bailian Co. plans to sign a land compensation agreement with Friendship Logistics, with a total compensation of 103 million yuan [19] Group 7 - Dayu Water-saving's subsidiary has been pre-awarded two high-standard farmland construction projects, with total expected amounts of 137 million yuan and 135 million yuan respectively [20] - Tianma Technology reported a total eel output of approximately 1197.15 tons in November, with sales prices ranging from 53,000 yuan/ton to 89,000 yuan/ton [21] - Guorui Technology's subsidiary has been shortlisted for the GXLF project with a bid of 76 million yuan [22] Group 8 - Qingdao Food's deputy general manager has resigned for personal reasons [23] - Guosheng Zhike plans to use up to 900 million yuan of idle funds for cash management [24] - Guodian Nanrui plans to use up to 23 billion yuan of idle funds for entrusted wealth management [25] Group 9 - Jiahuan Energy plans to merge its wholly-owned subsidiary, Zhejiang Jiahuan Hydrogen Peroxide Co., Ltd., through an overall absorption merger [26] - Ganyue Expressway reported vehicle toll service revenue of 309 million yuan for November [27] - Jinling Hotel's chairman has resigned due to work changes [28] Group 10 - Lisheng Pharmaceutical's subsidiary has received drug registration certificates for Apremilast Tablets [29] - Baotai has received a positive opinion from the European Medicines Agency for Gotenfia® for various inflammatory conditions [30] - ST Zhisheng has been awarded a smart city governance project with a bid amount of 104 million yuan [31] Group 11 - Chenxi Aviation and its related personnel have received administrative regulatory measures from the Shaanxi Securities Regulatory Bureau due to financial reporting issues [32] - Portong Medical has appointed Xia Canglan as the new deputy general manager [33] - Maide Medical plans to repurchase shares with a total amount between 20 million and 40 million yuan [34] Group 12 - Jimin Health plans to establish a joint venture with a total investment of 600 million yuan, focusing on AI and software development [35] - Beilu Pharmaceutical has received a drug registration certificate for Pioglitazone Metformin Tablets [36] - Hainan Mining plans to entrust the overall management of the Shiluo Iron Mine to a construction company for three years, with a total contract amount of approximately 818 million yuan [38] Group 13 - Huiyu Pharmaceutical has received a drug registration certificate for Nicardipine Hydrochloride Injection [39] - Baoland has received a government subsidy of 10 million yuan related to income [40] - Qingdao Port has terminated the acquisition of 100% equity in an oil company and 50% equity in Rizhao Shihua due to regulatory concerns [41]

北京宝兰德软件股份有限公司（以下简称"公司"） 近日收到政府补助款项 1,000 万元，属于与收益相关的政府补助。 二、补助的类型及其对公司的影响 根据《企业会计准则第 16 号——政府补助》的相关规定，上述补助确认为 与收益相关的政府补助，预计对公司经营业绩产生一定积极影响。上述政府补助 数据未经审计，具体的会计处理以及对公司损益的影响须以审计机构年度审计确 认后的结果为准。敬请广大投资者注意投资风险。 特此公告。 北京宝兰德软件股份有限公司董事会 证券代码：688058 证券简称：宝兰德 公告编号：2025-050 北京宝兰德软件股份有限公司 关于获得政府补助的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、获得补助的基本情况 2025 年 12 月 13 日 ...